A global network of non-profit organisations supporting those affected by Niemann-Pick diseases

Xenpozyme (olipudase alfa) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

NNPDF GOES VIRTUAL – NNPDF Family Support & Medical Conference 2022

Want to join the NNPDF Family Support & Medical Conference but can’t be there in person? VIRTUAL Conference registration...

Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD

Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD Paris, June 28, 2022. The European Commission (EC) has approved...